Using Real-World Evidence To Enhance Drug Development: Arterial Health Monitoring Innovations

Life Sciences, Drug Discovery & Development, Medical Device, Biomarkers,
  • Monday, December 02, 2024 | 1pm EST (12pm CST / 10am PST)
  • 60 min

As the pharmaceutical industry increasingly turns to real-world evidence to support drug development and regulatory decisions, the importance of accurate and comprehensive health monitoring cannot be overstated.

Arterial health is a key determinant of the effectiveness and safety of many therapies, particularly in the context of cardiovascular disease, diabetes and other chronic conditions. Central blood pressure and arterial stiffness serve as robust biomarkers for assessing the impact of new drugs on the vascular system, providing insights that traditional peripheral measurements cannot offer.

CONNEQT Pulse empowers pharmaceutical companies to collect precise RWE, facilitating more informed decisions in the drug development process from early-phase trials to post-market surveillance.

It is a cuff-based device that monitors arterial health through central blood pressure and pulse wave analysis (PWA), thus representing a significant advancement in this area. This webinar will explore how CONNEQT Pulse can be integrated into clinical trials and real-world studies to generate critical RWE that informs drug efficacy and safety profiles.

This webinar will provide a detailed look at the application of CONNEQT Pulse in drug development, its validation as a clinical tool and its potential to improve therapeutic outcomes through better-informed regulatory strategies.

Register for this webinar to discover how gathering real-world evidence can revolutionize drug development for cardiovascular diseases.

Speaker

Dr. Sanjeev Bhavnani, MD, FACC, Senior Cardiologist and Principal Investigator/AI Trials - Scripps Clinic

Dr. Sanjeev Bhavnani, MD, FACC, Senior Cardiologist and Principal Investigator/AI Trials - Scripps Clinic; Former Senior Medical Officer of Digital Health - US FDA

Dr. Sanjeev Bhavnani is a distinguished physician, digital health clinical trialist and policy strategist with over two decades of experience in advancing healthcare innovation through leadership roles across health systems, government and private sectors.

Specializing in the integration of digital health technologies (DHTs) and artificial intelligence/machine learning (AI/ML) into clinical practice, Dr. Bhavnani has successfully led multidisciplinary teams in the design, execution and management of high-impact clinical trials, resulting in multiple FDA approvals.

A passionate advocate for diversity, equity and inclusion (DE&I), Dr. Bhavnani is dedicated to pioneering inclusive healthcare solutions and shaping national policy to drive equitable access to cutting-edge medical innovations.

Message Presenter

Who Should Attend?

This webinar will appeal to professionals with the following job titles or those working in the following fields:

  • Drug and device development
  • Clinical trials/Clinical operations/Clinical trial planning and optimization
  • Regulatory affairs/Clinical affairs/Medical affairs
  • Clinical research
  • Principal Investigators
  • Medical Director
  • Trial Leader

What You Will Learn

Attendees will learn about:

  • How central blood pressure and pulse wave analysis offer critical insights for generating RWE in drug development
  • How accurate arterial health data enhances assessments of drug efficacy and safety in trials and real-world studies
  • How central blood pressure and arterial stiffness provide more precise vascular data than traditional peripheral measurements
  • How enhanced arterial biomarkers support better regulatory decisions and improved therapeutic outcomes across diverse populations

Xtalks Partner

Cardiex

Cardiex is a digital health technology company that develops and markets noninvasive patient monitoring technologies for assessing cardiovascular health.

Our pioneering SphygmoCor vascular biosensing technology measures arterial health by collecting clinically meaningful digital vascular biomarkers using novel sensors. These biomarkers represent key indicators of cardiovascular health including, but not limited to, central blood pressures, vascular stiffness, vascular age, and heart stress. SphygmoCor has been deployed in multiple clinical trials sponsored by pharmaceutical companies and healthcare systems to measure arterial health.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account